Tiziana Pressiani

12PUBLICATIONS
84CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursChemotherapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 07, 2026
Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores.

|Sep 26, 2026
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy.

|Apr 09, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab.

Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner

|Oct 18, 2024
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial.

Teresa Macarulla, Zhenggang Ren, Hong Jae Chon

|Oct 09, 2023
Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma.

Valentina Zanuso, Angelo Pirozzi, Rita Balsano

|Sep 21, 2022
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights.

Antonella Cammarota, Valentina Zanuso, Tiziana Pressiani

Pageof 2

Frequent Collaborators

11 joint publications

Lorenza Rimassa

5 joint publications

Antonella Cammarota

5 joint publications

Antonio D'Alessio

5 joint publications

Nicola Personeni